RxDoctor Payments Data

Norberto Alvarez, MD

Family Medicine · Laredo, TXNPI 1730383324

Payments from drug & device makers

$4,843in general payments, 2019–2025

Across 292 payments — averaging $16.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$542
  • Lilly USA, LLC$465
  • Novo Nordisk$429
  • Merck$360
  • GSK$346
  • Bayer$296
  • plus $2K from 35 others

What the payments were for

  • Food & beverage$4,76198%
  • Education$822%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,843 in reported general payments places this provider in the 85th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$168,284
Medicare patients
291
Services billed
1,893

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide310$369,196
JardianceEmpagliflozin237$302,639
JanuviaSitagliptin Phosphate232$249,871
LinzessLinaclotide195$176,738
TradjentaLinagliptin145$166,608
Trelegy ElliptaFluticasone/Umeclidin/Vilanter236$165,790
SynjardyEmpagliflozin/Metformin Hcl144$163,596
JanumetSitagliptin Phos/Metformin Hcl106$146,290
FarxigaDapagliflozin Propanediol121$145,957
KerendiaFinerenone106$138,524
EliquisApixaban135$113,875
MyrbetriqMirabegron117$107,265
RybelsusSemaglutide50$106,346
EntrestoSacubitril/Valsartan97$81,084
XareltoRivaroxaban56$70,994

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Synjardy, Synjardy Xr$161$649,619538 claims
Novo NordiskOzempic, Rybelsus$429$475,542360 claims
MerckJanuvia, Janumet, Belsomra$360$431,110376 claims
AbbVieLinzess, Vraylar$542$214,106221 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$346$190,310285 claims
AstraZenecaFarxiga, Breztri Aerosphere$110$159,051139 claims
BayerKerendia$296$138,524106 claims
PfizerEliquis, Premarin$31$125,055159 claims
Lilly USA, LLCMounjaro, Trulicity$465$114,98291 claims
Astellas Pharma US IncMyrbetriq$17$107,265117 claims
NovartisEntresto$77$81,08497 claims
Johnson & JohnsonXarelto$37$70,99456 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Laredo

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →